Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Ethypharm Pharmaceuticals Co. Ltd. currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action, which is assigned to 1 distinct examiner and 1 distinct art unit. This distribution reflects the company's current prosecution activities at the USPTO.
The busiest examiner for this portfolio is BASQUILL, SEAN M, who is responsible for the 1 pending office action. Because the portfolio is handled by 1 distinct examiner, this individual manages the company's active prosecution workload. This presence in 1 distinct art unit shows that the company's intellectual property strategy is currently focused on a specific technical area within the Biotechnology & Pharmaceuticals sector.
Practitioners should note that the portfolio's immediate trajectory is tied to the decisions of the busiest examiner. This lack of diversification across multiple art units or examiners means that the outcomes in this technology area will define the company's current patenting success. The current data reflects a specific approach to securing intellectual property rights. This concentration allows for a focused legal strategy but limits the breadth of the company's pending claims across different examination units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17776723 | PROCESS FOR PRODUCING AN ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION WITH COLONIC DELIVERY | BASQUILL, SEAN M | 29d overdue |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17776723 | PROCESS FOR PRODUCING AN ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION WITH COLONIC DELIVERY | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | 29d overdue | Pending | Oct 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial